Lipella Pharmaceuticals Inc.

The momentum for this stock is not very good. Lipella Pharmaceuticals Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Lipella Pharmaceuticals Inc..
Log in to see more information.
LIPO Fundamental Data by TradingView

News

Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York

Globe Newswire Company has two lead drug candidates for rare disease indications in IND approved phase 2 clinical trials using the 505(b)(2) pathwayPITTSBURGH, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Lipella...\n more…

Lipella Pharmaceuticals launches Oral Lichen Planus patient registry
Lipella Pharmaceuticals launches Oral Lichen Planus patient registry

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research
Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research

Globe Newswire Affecting about 6 million Americans, OLP is a chronic inflammatory disease affecting the mucous membranes of the mouthNo FDA-approved therapy currently exists for OLPPatient registry and OLP study...\n more…

Financial Review: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Sagimet Biosciences (NASDAQ:SGMT)
Financial Review: Lipella Pharmaceuticals (NASDAQ:LIPO) vs. Sagimet Biosciences (NASDAQ:SGMT)

Ticker Report Lipella Pharmaceuticals (NASDAQ:LIPO - Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare...\n more…

Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)
Lipella Pharmaceuticals Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.27 loss in 2Q 2023)

Simply Wall St Lipella Pharmaceuticals ( NASDAQ:LIPO ) Second Quarter 2024 Results Key Financial Results Revenue: US$136.4k (up 28...\n more…

LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024
LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q2 2024

InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nLipella Pharmaceuticals just reported results for the second quarter of 2024.\nThe post LIPO Stock Earnings: Lipella Pharmaceuticals...\n more…